You are about to leave Helsinn's Corporate US Website.

Please click 'Continue to external site' if you want to continue.

Our Approach

Helsinn has become one of the world’s leading cancer care and rare diseases companies, with a comprehensive portfolio of products and therapies helping to improve the lives of patients all around the world. We work with a host of longstanding worldwide partners who share our vision and values, with a unique business model combining integrated early- and late-stage licensing programs to complement our own drug discovery and development.

Helsinn's Business Strategy

Since its foundation, the Helsinn Group has had a unique integrated business model, focused on the in- and out-licensing of pharmaceuticals. We have recently started to build on our leading position in cancer care, expanding into cancer therapeutics.

Helsinn out-licenses its products to commercial partners in its global distribution network while promoting and distributing to the cancer-care community in the US through our subsidiary Helsinn Therapeutics.

 

We start the process with the identification of innovative NCEs in the development phase, which are then in-licensed by acquiring the worldwide rights.

Once we have a product aligned with our mission and portfolio, we utilize our integrated capabilities and our in-house knowledge to complete development, and secure marketing approvals and commercialization worldwide either directly or through our partners.

Corporate Social Responsibility

We are proud to take our
commitments seriously.

Learn More